I. Rouquette

发表

Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions

N. Girard, J. Blay, F. Galateau-Sallé, 2019, EBioMedicine.

Use of combined cardiac and lung ultrasound to predict weaning failure in elderly, high-risk cardiac patients: a pilot study

F. Mojoli, B. Bouhemad, S. Mongodi, 2020, Intensive Care Medicine.

Ultrasound for “Lung Monitoring” of Ventilated Patients

B. Bouhemad, S. Mongodi, I. Rouquette, 2015, Anesthesiology.

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

Jean Mosser, Franck Morin, Gérard Zalcman, 2016, The Lancet.

Biology of Human Tumors RhoB Determines Tumor Aggressiveness in a Murine EGFRL 858 R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer

G. Favre, I. Rouquette, T. Filleron, 2014 .

New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi‐Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center

N. Le Stang, N. Girard, A. Nicholson, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.

V. Plagnol, J. Mazières, G. Favre, 2019, Lung cancer.

MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung

N. Girard, S. Lantuejoul, J. Mazières, 2017, Oncotarget.

[The French mesothelioma network from 1998 to 2013].

N. Le Stang, F. Galateau-Sallé, P. Hainaut, 2014, Annales de pathologie.

[Lung cancer in women and pregnancy: towards a hormonal origin?].

J. Mazières, I. Rouquette, L. Brouchet, 2007, Revue des maladies respiratoires.

Alternative Processing of the U2 Small Nuclear RNA Produces a 19–22nt Fragment with Relevance for the Detection of Non-Small Cell Lung Cancer in Human Serum

A. Didier, J. Mazières, R. Escamilla, 2013, PloS one.

Specificities of Lung Adenocarcinoma in Women Who Have Never Smoked

P. Validire, J. Mazières, P. Hofman, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes

J. Mazières, J. Merlio, F. Escande, 2020, JTO clinical and research reports.

Blood stem cell transplantation to treat cystic lung light chain deposition disease

A. Didier, G. Prévot, R. Borie, 2015, European Respiratory Journal.

COVID-19 pneumonia: relationship between inflammation assessed by whole-body FDG PET/CT and short-term clinical outcome

J. Catineau, G. Chironi, F. Berthier, 2020, European Journal of Nuclear Medicine and Molecular Imaging.

Adenoid cystic carcinoma of the lung: interest of 18FDG PET/CT in the management of an atypical presentation.

A. Didier, J. Mazières, P. Rochaix, 2008, Lung cancer.

Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung.

J. Mazières, I. Rouquette, T. Filleron, 2016, Clinical lung cancer.

Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches

P. Brousset, J. Mazières, J. Solassol, 2017, Scientific Reports.

Glut-1 intensity and pattern of expression in thymic epithelial tumors are predictive of WHO subtypes.

N. Girard, T. Molina, A. Marx, 2015, Pathology, research and practice.

Rare epidermal growth factor receptor (EGFR) mutations in 10,117 patients with non-small cell lung cancer (NSCLC) evaluated by the French ERMETIC IFCT network: Clinical, molecular, and survival data.

J. Solassol, H. Blons, F. Escande, 2012 .

Un regard simple sur la biologie moléculaire du cancer bronchique : la thymidylate synthase (TS)

I. Rouquette, J. Mazières, 2011 .

c‐MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas

N. Girard, S. Lantuejoul, J. Mazières, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Multicenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraf ﬁ n-Embedded Tissue of Human Lung Cancer

B. Bellosillo, I. Kern, I. Rouquette, 2020 .

Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.

V. Plagnol, J. Mazières, G. Favre, 2019, Lung cancer.

[PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists].

N. Girard, F. Galateau-Sallé, S. Lantuejoul, 2018, Annales de pathologie.

Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1

N. Girard, F. Galateau-Sallé, T. Molina, 2019, Biomarker Research.

Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer

N. Le Stang, S. Lantuejoul, F. Penault-Llorca, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[Sarcoid-like granulomatosis in cancer patients treated with immune checkpoints inhibitors].

J. Mazières, G. Prévot, I. Rouquette, 2018, Revue des maladies respiratoires.

Takotsubo cardiomyopathy and anaesthesia.

I. Rouquette, M. Christias, M. Scemama, 2010, British journal of anaesthesia.

Micronodular thymic carcinoma with lymphoid hyperplasia: relevance of immunohistochemistry with a small panel of antibodies for diagnosis—a RYTHMIC study

N. Girard, T. Molina, A. Marx, 2021, Virchows Archiv.

Impact of expert pathologic review of thymic epithelial tumours on diagnosis and management in a real-life setting: A RYTHMIC study.

N. Girard, T. Molina, A. Marx, 2020, European journal of cancer.

Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACSé phase II trial.

G. Ferretti, S. Lantuejoul, G. Vassal, 2015 .

Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.

S. Lantuejoul, O. Molinier, J. Mazières, 2019, Clinical lung cancer.

Quality of triage.

J. Tourtier, Y. Auroy, I. Rouquette, 2010, Injury.

A comparison of low vs conventional‐dose heparin for minimal cardiopulmonary bypass in coronary artery bypass grafting surgery

Y. Fromes, I. Rouquette, O. Bical, 2011, Anaesthesia.

A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms.

J. Pignon, J. Mosser, I. Bièche, 2014, The Journal of molecular diagnostics : JMD.

High-throughput detection of clinically targetable alterations using next-generation sequencing

P. Brousset, J. Solassol, V. Costes, 2017, Oncotarget.

Papillary neoplasm of the endolymphatic sac in a patient with von Hippel-Lindau disease.

I. Rouquette, M. Delisle, E. Yardeni, 1994, Journal of clinical pathology.

On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.

E. Brambilla, S. Lantuejoul, J. Sabourin, 2014, Lung cancer.

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.

S. Peters, E. Felip, J. Mazières, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.

J. Mazières, G. Favre, I. Rouquette, 2018, Lung cancer.

[Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].

S. Lantuejoul, J. Adam, A. Cazes, 2017, Annales de pathologie.

Disentangling heterogeneity of Malignant Pleural Mesothelioma through deep integrative omics analyses

Erik N. Bergstrom, P. Courtiol, C. Maussion, 2021, bioRxiv.

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.

J-L Pretet, I. Bièche, J. Solassol, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches

P. Brousset, J. Mazières, J. Solassol, 2017, Scientific Reports.

[New WHO classification of lung adenocarcinoma and preneoplasia].

W. Travis, E. Brambilla, S. Lantuejoul, 2016, Annales de pathologie.

RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer

J. Mazières, G. Favre, I. Rouquette, 2014, Clinical Cancer Research.

DNA replication stress response involving PLK1, CDC6, POLQ, RAD51 and CLASPIN upregulation prognoses the outcome of early/mid-stage non-small cell lung cancer patients

J. Mazières, P. Pasero, I. Rouquette, 2012, Oncogenesis.

PL04a.04: Multicentric French Harmonization Study for PD-L1 IHC Testing in NSCLC

S. Lantuejoul, F. Penault-Llorca, J. Adam, 2017 .

Validation of the QR1 Antibody for the Evaluation of PD-L1 Expression in Non–Small Cell Lung Adenocarcinomas

S. Lantuejoul, C. Mascaux, I. Rouquette, 2020, Applied immunohistochemistry & molecular morphology : AIMM.

P2.09-17 Real-World Concordance Across Pathologists for PD-L1 Scoring in Non-Small Cell Lung Cancer: Results from a Large Nationwide Initiative

M. Copin, S. Lantuejoul, F. Penault-Llorca, 2019, Journal of Thoracic Oncology.

Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program

J. Mosser, H. Blons, J. Merlio, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial

P. Hainaut, B. Milleron, E. Brambilla, 2012, Clinical Cancer Research.

Comprehensive molecular and pathological evaluation of transitional mesothelioma assisted by deep learning approach: a multi institutional study of the International Mesothelioma Panel from MESOPATH Reference Center.

G. Wainrib, P. Courtiol, C. Maussion, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non–Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway

E. Brambilla, J. Camonis, J. Pujol, 2012, Molecular Cancer Therapeutics.

Molecular Medicine in Practice High TUBB 3 Expression , an Independent Prognostic Marker in Patients with Early Non – Small Cell Lung Cancer Treated by Preoperative Chemotherapy , Is Regulated by KRas Signaling Pathway

E. Brambilla, J. Camonis, J. Pujol, 2012 .

Basic fibroblast growth factor-2/beta3 integrin expression profile: signature of local progression after chemoradiotherapy for patients with locally advanced non-small-cell lung cancer.

E. Cohen-Jonathan-Moyal, J. Mazières, J. Armand, 2009, International journal of radiation oncology, biology, physics.

[Is symptom of post-dural puncture syndrome reproductible in the same patient?].

D. Benhamou, J. Tourtier, I. Rouquette, 2003, Annales francaises d'anesthesie et de reanimation.

French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas

N. Le Stang, F. Galateau-Sallé, S. Lantuejoul, 2015, European Respiratory Journal.

[An unusual mediastinal mass].

A. Didier, J. Mazières, I. Rouquette, 2014, Revue des maladies respiratoires.

Multi-Center Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer.

B. Bellosillo, I. Kern, I. Rouquette, 2019, The Journal of molecular diagnostics : JMD.

The prognostic significance of lymphovascular invasion on biopsy specimens in lung cancer treated with definitive chemoradiotherapy.

J. Mazières, C. Toulas, J. Bachaud, 2012, Clinical lung cancer.

Ultra-sensitive EGFRT790M Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring EGFRdel19 Mutations and Treated with First-generation TKIs

P. Brousset, J. Mazières, J. Solassol, 2019, Clinical Cancer Research.

Late diagnosis of congenital methemoglobinemia in an elderly patient during cardiac surgery.

B. Bouhemad, I. Rouquette, P. Deleuze, 2014, Journal of cardiothoracic and vascular anesthesia.

Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma.

P. Validire, J. Soria, A. Bernheim, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Characteristics of lung cancer in women: importance of hormonal and growth factors.

A. Didier, J. Mazières, J. Laurent, 2012, Lung cancer.

Complex communicating bronchopulmonary foregut malformation with pancreatic heterotopy depicted with fetal magnetic resonance imaging: a case report.

I. Rouquette, P. Galinier, Q. Ballouhey, 2012, Journal of pediatric surgery.

Diagnostic value of bronchoscopy, CT and transbronchial biopsies in diffuse pulmonary lymphangiomatosis: case report and review of the literature.

A. Didier, J. Mazières, I. Rouquette, 2005, Clinical radiology.

[Endonasal microsurgery of antro-choanal polyps].

I. Rouquette, D. Chevalier, J. Piquet, 1992, Acta oto-rhino-laryngologica Belgica.

[Alveolar capillary dysplasia and persistent pulmonary hypertension of the newborn].

I. Rouquette, Y. Dulac, M. Marcoux, 2007, Archives des maladies du coeur et des vaisseaux.

Improvement of the cytological diagnostic accuracy of follicular thyroid lesions by the use of the Ki‐67 proliferative index in addition to cytokeratin‐19 and HBME‐1 immunomarkers: a study of 61 cases of liquid‐based FNA cytology with histological controls

I. Rouquette, M. Delisle, E. Bérard, 2014, Cytopathology : official journal of the British Society for Clinical Cytology.

Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial

O. Molinier, J. Mazières, G. Zalcman, 2020, Clinical Cancer Research.

Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer: A Phase I Study.

J. Mazières, C. Toulas, I. Rouquette, 2017, Clinical lung cancer.

J. Mazières, G. Favre, E. Clermont-Taranchon, 2016, EMBO molecular medicine.

Cytoplasmic p27Kip1 promotes tumorigenesis via suppression of RhoB activity

S. Cabantous, J. Mazières, Hue Lee, 2018, The Journal of pathology.

[Black oesophagus, a rare event in intensive care unit].

I. Rouquette, L. Brinquin, J. Rousseau, 2004, Annales Francaise d'Anesthesie et de Reanimation.

Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity

P. Courtiol, C. Maussion, N. Le Stang, 2023, Nature Genetics.

Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts).

J. Mosser, F. Penault-Llorca, J. Soria, 2013 .

Lung Ultrasound for Early Diagnosis of Ventilator-Associated Pneumonia.

B. Misset, F. Mojoli, B. Bouhemad, 2016, Chest.

High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets.

N. Girard, S. Lantuejoul, J. Mazières, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Soft tissue tumors following traumatic injury: two observations of interest for the medicolegal causality.

I. Rouquette, D. Rougé, R. Durroux, 1998, American Journal of Forensic Medicine and Pathology.

FP09.05 Driver Oncogenic Alterations and Indoor Radon in NSCLC Patients From the IFCT Biomarker Cohort: Bioradon France Study

J. Mosser, D. Planchard, J. Merlio, 2021 .

EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice

J. Mosser, J. Mazières, G. Zalcman, 2017, European Respiratory Journal.

Thymoma and solid-organ transplantation.

A. Didier, J. Mazières, L. Rostaing, 2012, Lung Cancer.

[A brief overview of a lung cancer biomarker: thymidylate synthase].

J. Mazières, I. Rouquette, 2011, Revue des maladies respiratoires.

Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.

J. Mosser, H. Blons, J. Merlio, 2017 .

Multicenter Evaluation of a Novel ROS1 Immunohistochemistry Assay (SP384) for Detection of ROS1 Rearrangements in a Large Cohort of Lung Adenocarcinoma Patients.

C. Marquette, J. Mazières, J. Sabourin, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Recurrence of sarcoidosis in a human lung allograft.

A. Didier, P. Carré, D. Durand, 1995, Transplantation proceedings.

Reversible myocardial dysfunction after exertional heat stroke

I. Rouquette, E. Schiano, L. Brinquin, 2001, Intensive Care Medicine.

[Rythmic-pathology: the French national pathology network for thymic epithelial tumours].

N. Girard, T. Molina, A. Marx, 2014, Annales de pathologie.

[Delay in post-anesthetic recovery in neurosurgery: which diagnostic imaging?].

I. Rouquette, P. Schiano, J. Lévecque, 1999, Annales francaises d'anesthesie et de reanimation.

c‐MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas

N. Girard, S. Lantuejoul, J. Mazières, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Langerhans Cell Histiocytosis of the Thyroid is a Rare Entity, but an Association with a Papillary Thyroid Carcinoma is Often Described

I. Rouquette, É. Serrano, S. Vergez, 2010, Endocrine pathology.

Inequity in access to personalized medicine in France: Evidences from analysis of geo variations in the access to molecular profiling among advanced non-small-cell lung cancer patients: Results from the IFCT Biomarkers France Study

W. Weeks, B. Ventelou, F. Barlesi, 2020, PloS one.

RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer

J. Mazières, G. Favre, I. Rouquette, 2014, Clinical Cancer Research.

[Thymoma and squamous thymic carcinoma diagnosis; experience from the RYTHMIC network].

N. Girard, T. Molina, A. Marx, 2020, Annales de pathologie.

Non-small cell lung cancer, early stage

L. Bubendorf, T. Yamanaka, M. Okada, 2012 .

[An unusual cause of infiltrative lung disease].

I. Rouquette, G. Martin-Blondel, B. Marchou, 2009, La Revue de medecine interne.